Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will give a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference. This event is set for September 12-14, 2022, during which management will host investor meetings.

Nabriva is focused on developing innovative anti-infective agents. Their FDA-approved product, XENLETA^®, is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia, while they are also developing CONTEPO™ for complicated urinary tract infections.

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference. Management will also host investor meetings September 12-14, 2022.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA^® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO^® (tedizolid phosphate) in the United States and certain of its territories.

CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com

FAQ

What will Nabriva Therapeutics discuss at the H.C. Wainwright Conference?

Nabriva Therapeutics will provide a company overview and business update at the conference.

When is the H.C. Wainwright 24th Annual Global Investment Conference?

The conference will take place from September 12-14, 2022.

What is the significance of XENLETA for Nabriva Therapeutics?

XENLETA is the first systemic pleuromutilin antibiotic approved by the FDA for treating community-acquired bacterial pneumonia.

What other products is Nabriva Therapeutics developing?

Nabriva is developing CONTEPO™, a potential first-in-class antibiotic for complicated urinary tract infections.

Who is the CEO of Nabriva Therapeutics?

Ted Schroeder is the CEO of Nabriva Therapeutics.